CA2185394A1 - Biotinderivate - Google Patents

Biotinderivate

Info

Publication number
CA2185394A1
CA2185394A1 CA002185394A CA2185394A CA2185394A1 CA 2185394 A1 CA2185394 A1 CA 2185394A1 CA 002185394 A CA002185394 A CA 002185394A CA 2185394 A CA2185394 A CA 2185394A CA 2185394 A1 CA2185394 A1 CA 2185394A1
Authority
CA
Canada
Prior art keywords
gly
asp
arg
absent
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002185394A
Other languages
French (fr)
Other versions
CA2185394C (en
Inventor
Alfred Jonczyk
Simon Goodman
Beate Diefenbach
Horst Kessler
Dirk Finsinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2185394A1 publication Critical patent/CA2185394A1/en
Application granted granted Critical
Publication of CA2185394C publication Critical patent/CA2185394C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Biotin compounds of the formula I (see formula I) is which Q is absent, -NH-(CH2)n-CO or -NH-(CH2)n-NH- and R1 is X-Arg-Gly-Asp-Y, A-Cys(R2)-B-U or cyclo-(Arg-Gly-Asp-Z), where Z is bonded in the side chain to Q or, if Q is absent, to biotin, and A, B, U, X, Y, Z and n have the meanings stated is Claim 1, and their salts can be used as integrin inhibitors, in particular for the prophylaxis and treatment of disorders of the circulation, for thrombosis, myocardial infarct, coronary heart diseases, arteriosclerosis, angiogenic disorders and is tumour therapy.
CA002185394A 1995-09-14 1996-09-12 Biotinderivate Expired - Fee Related CA2185394C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19534016A DE19534016A1 (en) 1995-09-14 1995-09-14 Biotin derivatives
DE19534016.7 1995-09-14

Publications (2)

Publication Number Publication Date
CA2185394A1 true CA2185394A1 (en) 1997-03-15
CA2185394C CA2185394C (en) 2007-05-01

Family

ID=7772112

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185394A Expired - Fee Related CA2185394C (en) 1995-09-14 1996-09-12 Biotinderivate

Country Status (23)

Country Link
EP (1) EP0771818B1 (en)
JP (1) JP4127325B2 (en)
KR (1) KR970015597A (en)
CN (1) CN1168738C (en)
AT (1) ATE215558T1 (en)
AU (1) AU719307B2 (en)
BR (1) BR9603741A (en)
CA (1) CA2185394C (en)
CZ (1) CZ291506B6 (en)
DE (2) DE19534016A1 (en)
DK (1) DK0771818T3 (en)
ES (1) ES2174007T3 (en)
HU (1) HUP9602223A3 (en)
MX (1) MX9604019A (en)
NO (1) NO314694B1 (en)
PL (1) PL316069A1 (en)
PT (1) PT771818E (en)
RU (1) RU2171807C2 (en)
SI (1) SI0771818T1 (en)
SK (1) SK283129B6 (en)
TW (1) TW517063B (en)
UA (1) UA41981C2 (en)
ZA (1) ZA967765B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
KR100778633B1 (en) * 2007-04-13 2007-11-28 성균관대학교산학협력단 Glp-1 derivative linked biotin and biotin-polyethylene glycol, method for the preparation thereof and pharmaceutical composition comprising the same
WO2009124754A1 (en) * 2008-04-08 2009-10-15 Merck Patent Gmbh Compositions containing cyclic peptides and methods of use
CN108956790A (en) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 Application of one group of amino acid tags object in acute kidney injury diagnostic kit
CN113827591B (en) * 2021-11-09 2023-06-09 上海市肺科医院 Application of biotin in preparation of medicines for treating sepsis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315076B2 (en) * 1973-09-27 1978-05-22
JP2945680B2 (en) * 1988-09-09 1999-09-06 旭硝子株式会社 Peptide derivatives and their uses
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
DE4310643A1 (en) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
DE4336758A1 (en) * 1993-10-28 1995-05-04 Merck Patent Gmbh Linear Adhesion Inhibitors

Also Published As

Publication number Publication date
NO963851L (en) 1997-03-17
PL316069A1 (en) 1997-03-17
SK283129B6 (en) 2003-02-04
ES2174007T3 (en) 2002-11-01
HUP9602223A2 (en) 1997-06-30
EP0771818B1 (en) 2002-04-03
KR970015597A (en) 1997-04-28
NO963851D0 (en) 1996-09-13
JP4127325B2 (en) 2008-07-30
EP0771818A2 (en) 1997-05-07
JPH09124692A (en) 1997-05-13
CZ262996A3 (en) 1998-02-18
AU6551896A (en) 1997-03-20
AU719307B2 (en) 2000-05-04
DE19534016A1 (en) 1997-03-20
RU2171807C2 (en) 2001-08-10
UA41981C2 (en) 2001-10-15
TW517063B (en) 2003-01-11
PT771818E (en) 2002-09-30
ZA967765B (en) 1997-03-26
CZ291506B6 (en) 2003-03-12
EP0771818A3 (en) 1997-07-02
DE59608995D1 (en) 2002-05-08
SI0771818T1 (en) 2002-10-31
BR9603741A (en) 1998-06-02
NO314694B1 (en) 2003-05-05
SK115696A3 (en) 1997-05-07
CN1168738C (en) 2004-09-29
MX9604019A (en) 1997-03-29
CN1153784A (en) 1997-07-09
HUP9602223A3 (en) 1998-03-02
DK0771818T3 (en) 2002-07-29
CA2185394C (en) 2007-05-01
HU9602223D0 (en) 1996-10-28
ATE215558T1 (en) 2002-04-15

Similar Documents

Publication Publication Date Title
SE9704709D0 (en) Pharmaceutically active compounds
CA2137832A1 (en) Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase
ITMI922953A1 (en) DOUBLE BIOLOGICAL ACTIVITY OF NO SYNTHASIS AND CYCLOOXYGENES PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM.
CA2080705A1 (en) Substituted pyrimidines
NO20010203L (en) Diacylhydrazine derivatives as integrin inhibitors
ZA94615B (en) Piperazine derivatives
CA2280727A1 (en) Bicyclic amino acids
CA2175767A1 (en) Adhesion receptor antagonists
CA2148194A1 (en) Cyclopeptides of the formula i
EP0702557A4 (en) Therapeutic inhibitor of vascular smooth muscle cells
CA2185394A1 (en) Biotinderivate
MY133785A (en) Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias
WO2003031447A3 (en) Pyrimidine derivatives
AU4163793A (en) Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
NO20000016L (en) Cyclic azapeptides with angiogenic activity
ZA862484B (en) Peptides
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
AU7750194A (en) Linear adhesion inhibitors
CA2099497A1 (en) Peptides with anticoagulant activity
WO1999010371A3 (en) Cyclopeptide derivatives as adhesion inhibitors
AU4833085A (en) Pyridine derivatives
NO944809L (en) Biologically active ureido derivatives useful in the treatment of lentivirus-induced disease
WO1990010006A3 (en) NOVEL β-METHOXYACRYLATES, THEIR PRODUCTION AND USE
TR200103660T2 (en) New bispidin compounds useful in the treatment of cardiac arrhythmias

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150914